These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31293599)

  • 1.
    Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
    Front Immunol; 2019; 10():1456. PubMed ID: 31293599
    [No Abstract]   [Full Text] [Related]  

  • 2. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
    Gupta S; Garg NJ
    PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
    Gupta S; Garg NJ
    Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
    Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
    Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
    Chowdhury IH; Lokugamage N; Garg NJ
    Front Immunol; 2020; 11():595039. PubMed ID: 33414785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.
    Gupta S; Garg NJ
    PLoS One; 2013; 8(3):e59434. PubMed ID: 23555672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
    Bhatia V; Garg NJ
    Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
    Gupta S; Garg NJ
    PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease.
    Gupta S; Wan X; Zago MP; Sellers VC; Silva TS; Assiah D; Dhiman M; Nuñez S; Petersen JR; Vázquez-Chagoyán JC; Estrada-Franco JG; Garg NJ
    PLoS Negl Trop Dis; 2013; 7(1):e2018. PubMed ID: 23350012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.
    Gupta S; Silva TS; Osizugbo JE; Tucker L; Spratt HM; Garg NJ
    Infect Immun; 2014 Apr; 82(4):1382-9. PubMed ID: 24421046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.
    Aparicio-Burgos JE; Zepeda-Escobar JA; de Oca-Jimenez RM; Estrada-Franco JG; Barbabosa-Pliego A; Ochoa-García L; Alejandre-Aguilar R; Rivas N; Peñuelas-Rivas G; Val-Arreola M; Gupta S; Salazar-García F; Garg NJ; Vázquez-Chagoyán JC
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003625. PubMed ID: 25853654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.
    Aparicio-Burgos JE; Ochoa-García L; Zepeda-Escobar JA; Gupta S; Dhiman M; Martínez JS; de Oca-Jiménez RM; Val Arreola M; Barbabosa-Pliego A; Vázquez-Chagoyán JC; Garg NJ
    PLoS Negl Trop Dis; 2011; 5(5):e1050. PubMed ID: 21625470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression.
    Gupta S; Smith C; Auclair S; Delgadillo Ade J; Garg NJ
    PLoS One; 2015; 10(6):e0130562. PubMed ID: 26075398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
    de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
    Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-Based Nano-Immunotherapy Controls Parasite Persistence, Inflammatory and Oxidative Stress, and Cardiac Fibrosis, the Hallmarks of Chronic Chagas Cardiomyopathy, in A Mouse Model of
    Lokugamage N; Choudhuri S; Davies C; Chowdhury IH; Garg NJ
    Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32098116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
    Basso B; Marini V
    Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening.
    Bhatia V; Sinha M; Luxon B; Garg N
    Infect Immun; 2004 Nov; 72(11):6245-54. PubMed ID: 15501750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.
    Eickhoff CS; Zhang X; Vasconcelos JR; Motz RG; Sullivan NL; O'Shea K; Pozzi N; Gohara DW; Blase JR; Di Cera E; Hoft DF
    PLoS Pathog; 2016 Sep; 12(9):e1005896. PubMed ID: 27642757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.